Literature DB >> 11827247

Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes.

Christopher M Dezii1, Hugh Kawabata, Michelle Tran.   

Abstract

BACKGROUND: We evaluated differences in adherence and persistence with prescribed therapy of once-daily (OD) dosing compared with twice-daily (BID) dosing of glipizide in patients with type 2 diabetes.
METHODS: The study cohort was derived from a pharmacy benefit manager claims database. Patients new to extended-release gastrointestinal therapeutic system (GITS) and immediate-release glipizide therapy were identified and followed for 1 year. Adherence indices (AIs) were calculated and persistence curves were constructed.
RESULTS: Adherence indices rates were 60.5% in the GITS OD cohort and 52.0% in the BID cohort. Rates of persistence at 12 months were 44.4% in the GITS OD cohort vs 35.8% in the BID cohort.
CONCLUSION: Initiation of OD pharmacotherapy results in better adherence and persistence compared with a BID regimen, despite a greater daily pill burden in the OD cohort. These data suggest that dosing frequency exerts a greater impact on patient adherence and persistence than number of tablets per dose.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11827247

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  29 in total

Review 1.  The impact of medication regimen factors on adherence to chronic treatment: a review of literature.

Authors:  Karen S Ingersoll; Jessye Cohen
Journal:  J Behav Med       Date:  2008-01-19

Review 2.  Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population.

Authors:  Ginés Sanz; Valentin Fuster
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-12-23

3.  Haemoglobin A1c goal attainment in relation to dose in patients with diabetes mellitus taking metformin: a nested, case-control study.

Authors:  Fernie J A Penning-van Beest; Bruce H R Wolffenbuttel; Ron M C Herings
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 4.  Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence.

Authors:  Israel Hartman
Journal:  Clin Med Res       Date:  2008-09-18

5.  How to use pharmacy claims data to measure patient nonadherence? The example of oral diabetics in therapy of type 2 diabetes mellitus.

Authors:  Thomas Wilke; Antje Groth; Sabrina Mueller; Dallas Reese; Roland Linder; Susanne Ahrens; Frank Verheyen
Journal:  Eur J Health Econ       Date:  2012-07-20

6.  Self-reported medication and lifestyle adherence in Hungarian patients with Type 2 diabetes.

Authors:  Balázs Hankó; Margit Kázmér; Péter Kumli; Zsuzsanna Hrágyel; Antal Samu; Zoltán Vincze; Romána Zelkó
Journal:  Pharm World Sci       Date:  2006-12-23

7.  Challenges of adherence and persistence with iron chelation therapy.

Authors:  John B Porter; Michael Evangeli; Amal El-Beshlawy
Journal:  Int J Hematol       Date:  2011-10-13       Impact factor: 2.490

Review 8.  Medication adherence and heart failure.

Authors:  Eric M Riles; Anuja V Jain; A Mark Fendrick
Journal:  Curr Cardiol Rep       Date:  2014-03       Impact factor: 2.931

9.  A retrospective database analysis of insulin use patterns in insulin-naïve patients with type 2 diabetes initiating basal insulin or mixtures.

Authors:  Machaon M K Bonafede; Anupama Kalsekar; Manjiri Pawaskar; Kimberly M Ruiz; Amelito M Torres; Karen R Kelly; Suellen M Curkendall
Journal:  Patient Prefer Adherence       Date:  2010-06-24       Impact factor: 2.711

Review 10.  Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement.

Authors:  James Swanson
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.